Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 9Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Non-Hodgkin 6Hematologic Neoplasms 6Multiple Myeloma 5Lymphoma, Follicular 5Hodgkin Disease 5Burkitt Lymphoma 5Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Lymphoma, T-Cell, Cutaneous 3Lymphoma, B-Cell 3Lymphoma 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Waldenstrom Macroglobulinemia 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Neoplasms 2Mycosis Fungoides 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

cabozantinib 1Specimen Handling 1Platinum Compounds 1Nivolumab 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lupus Erythematosus, Systemic × Ipilimumab × Other hematologic neoplasm × Clear all
NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

National Cancer Institute (NCI)

Phase 1 Recruiting
300 enrolled
Other hematologic neoplasm

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡